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Followed by Peripheral Stem Cell Rescue for High-Risk,
Locally Advanced/Inflammatory, and Metastatic
Breast Cancer
A. VanderWalde,1 W. Ye,2 P. Frankel,2 D. Asuncion,5 L. Leong,1 T. Luu,1 R. Morgan,1
P. Twardowski,1 M. Koczywas,1 R. Pezner,3 I. B. Paz,4 K. Margolin,6 J. Wong,3 J. H. Doroshow,7
S. Forman,8 S. Shibata,1 G. Somlo1Patients with high-risk locally advanced/inflammatory and oligometastatic (#3 sites) breast cancer frequently re-
lapse or experience early progression. High-dose chemotherapy combined with peripheral stem cell rescue may
prolong progression-free survival/relapse-free survival (PFS/RFS) and overall survival (OS). In this study, patients
initiated high-dose chemotherapy with STAMP-V (carboplatin, thiotepa, and cyclophosphamide), ACT (doxoru-
bicin, paclitaxel, and cyclophosphamide), or tandemmelphalan and STAMP-V. Eighty-six patients were diagnosed
with locally advanced/inflammatory (17 inflammatory) breast cancer, and 12were diagnosedwith oligometastatic
breast cancer. Median follow-up was 84 months (range, 6-136 months) for patients with locally advanced cancer
and 40months (range, 24-62months) for thosewith metastatic cancer. In the patients with locally advanced can-
cer, 5-year RFS andOSwere 53% (95%CI, 41%-63%) and 71% (95%CI, 60%-80%), respectively, hormone recep-
torswerepositive in 74%, andHER2overexpressionwas seen in23%. Inmultivariate analysis, hormone receptor–
positive disease and lower stagewere associatedwith better 5-yearRFS (60% for ER [estrogen receptor]/PR [pro-
gesterone receptor]-positive versus 30% for ER/PR-negative; P\.01) andOS (83% for ER/PR-positive versus 38%
for ER/PR-negative; P\ .001). In the patients with metastatic cancer, 3-year PFS and OS were 49% (95% CI,
19%-73%) and 73% (95%CI, 38%-91%), respectively. The favorable long-term RFS/PFS andOS for high-dose che-
motherapy with peripheral stem cell rescue in this selected patient population reflect the relative safety of the
procedure andwarrant validation indefined subgroups throughprospective, randomized,multi-institutional trials.
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Breast cancer is the leading cause of cancer death in
women worldwide [1]. In patients with locally ad-
vanced breast cancer (LABC), the risk of recurrence
is high, and the estimated 10-year overall survival
(OS) of patients with stage III disease is only 50%
[2]. In patients with $10 axillary nodal metastases
(stage IIIC), the risk of relapse is even higher; 15-year
disease-free survival (DFS) is 26% with adjuvant
anthracycline-based chemotherapy [3]. Patients with
inflammatory breast cancer (IBC) have the worst prog-
nosis, with a 5-yearOS of 40% [4]. Once distantmetas-
tases develop, the median survival is 18-24 months,
with only 14.5% of patients surviving for 5 years [4,5].
High-dose chemotherapy (HDCT) followed by
autologous peripheral blood progenitor cell (PBPC)
rescue has been compared with standard-dose1273
1274 Biol Blood Marrow Transplant 18:1273-1280, 2012A. VanderWalde et al.chemotherapy in trials, but the approach remains con-
troversial. Data from trials of some of the earliest reg-
imens suggested an unacceptably high early mortality
rate, up to 10% [6]. Although reports of 3-year RFS
in high-risk breast cancer approached 70% in early-
phase trials and retrospective registry trials [6-12],
possible selection bias in the determination of who
receives HDCT has been demonstrated [13]. Ran-
domized controlled trials (RCTs) have demonstrated
a significantly improved event-free survival (EFS) at
3, 4, and 5 years after treatment withHDCT; however,
no OS benefit has been apparent [14].
We have conducted a number of HDCT protocols
with PBPC rescue aimed at either LABC/IBC patients
(in accordance with American Joint Committee on
Cancer version 7, with an estimated risk of progression
of .50% at 5 years), or focusing on oligometastatic
stage IV breast cancer (MBC) to determine the
effect on relapse-free survival/progression-free sur-
vival (RFS/PFS) and OS in patients with high-risk or
oligometastatic MBC, as well as to delineate safety.
Here we report long-term safety and efficacy data for
patients treated prospectively with HDCT regimens
either on a randomized trial comparing doxorubicin,
paclitaxel, and cyclophosphamide (ACT) [15,16]
versus carboplatin, thiotepa, and cyclophosphamide
(STAMP-V) [17] or on a subsequent trial of tandem
melphalan and STAMP-V [18].METHODS
Patients
Patients treated with HDCT followed by PBPC
rescue on 2 sequentially developed protocols at City
of Hope Medical Center between 1999 and 2009 are
included in this report. The first HDCT protocol ran-
domized patients with LABC/IBC (stage IIIA-C) be-
tween a novel regimen of ACT and STAMP-V, with
enrollment starting in February 1999. The ACT arm
was closed in December 2003 due to toxicity concerns
(primarily mucositis requiring narcotics). All study
patients subsequently received STAMP-V through
December 2007. The study included a second ran-
domization between bisphosphonate pamidronate ver-
sus no pamidronate. The second protocol, which
consisted of high-dose melphalan followed by
STAMP-V as tandem HDCT, enrolled patients with
LABC/IBC and MBC (with at least partial response)
between September 2005 and November 2009. All pa-
tients participating in these City of Hope Medical
Center Institutional Review Board–approved trials
provided written voluntary informed consent.
On both protocols, conventional adjuvant chemo-
therapy (maximum allowed dose of doxorubicin,#240
mg/m2) was required\12 months before enrollment
for LABC/IBC. Stage IV patients were limited tothose who had oligometastatic disease (#3 organ sites
involved with metastases, regardless of the number of
lesions per organ) before induction therapy and#3 to-
tal residual lesions after induction chemotherapy (eg, 3
bone lesions: 1 bone, 1 liver, and 1 skin lesion) within 6
months before enrollment. Inclusion criteria for both
studies included a Karnofsky performance status of
$80%, age#65 years, adequate cardiac (left ventricu-
lar ejection fraction $55%), renal (creatinine clear-
ance $70 mL/min), hepatic (serum aspartate
aminotransferase and alanine aminotransferase #2
times the upper limit of normal), and pulmonary func-
tion, as well as adequate blood counts (neutrophyl
count of 1000 m/L and platelet count of 100,000 m/L).
Treatment
Induction chemotherapy and PBPCs
All patients with LABC/IBC received definitive
treatment before enrollment, including surgery and
chemotherapy. Patients with stage IV disease com-
pleted therapy for their metastatic breast cancer $4
weeks before enrollment. Methods of PBPC collection
have been described previously [11]. The minimum
cell dose required for transplantation was 2  106
CD341 cells/kg with the single HDCT regimens
and 4 106 CD341 cells/kg with the tandem regimen.
HDCT regimens
The ACT regimen consisted of doxorubicin 41.25
mg/m2 daily given as a continuous i.v. infusion over 96
hours on day 29 to day 26, cyclophosphamide 100
mg/kg i.v. on day 25, and paclitaxel 725 mg/m2 i.v.
over 24 hours on day 24. On day 22, 25% of PBPCs
were reinfused, in view of our previous published
experience suggesting that potentially ‘‘sacrificial’’ early
reinfusion of a fraction of PBPCs leads to earlier granu-
locyte recovery [19]. The remaining 75% of PBPCs
were reinfused on day 0. Granulocyte colony stimulat-
ing factor (G-CSF) at 5 mg/kg i.v. was started on day 0.
The other 2 regimens involved STAMP-V alone
(in the first protocol) or after melphalan as part of
a tandem transplant (second protocol). STAMP-V
comprised cyclophosphamide 1.5 g/m2/day, carbopla-
tin 200mg/m2/day, and thiotepa 125mg/m2/day given
as a continuous i.v. infusion for 96 hours on days 27
through 24. For the single transplant regimen, 25%
of PBPCswere reinfused on day22, and the remaining
75% were infused on day 0. G-CSF 5 mg/kg i.v. was
started on day 0.
The tandem protocol allowed for an infusion of
trastuzumab 8 mg/kg, for patients with HER2-
positive tumors, administered on day 22 of cycle 1.
All patients received melphalan 150 mg/m2 i.v. over
30 minutes on day -1. On day 0, 50% of PBPCs were
reinfused, and daily G-CSF administration was begun.
After recovery of marrow function, patients proceeded
Table 1. Patient Characteristics
Variable Stage III (n 5 86) Stage IV (n 5 12)
Demographic characteristics, median
(range)
Age, years 50 (28-66) 44 (32-57)
Follow-up for living patients,
months
84 (6-136) 40 (24-62)
Time from diagnosis to protocol
treatment, months
8.1 (4.6-39.2) 21.3 (7.3-106.4)
Race, n (%)
Asian 3 (3) 2 (17)
Black 3 (3) 1 (8)
Caucasian 59 (69) 8 (67)
Hispanic 21 (24) 1 (8)
Disease characteristics, n (%)
Stage
IIIA 13 (15) 0
IIIB 9 (10) 0
IIIC 64 (74) 0
IV 0 12 (100)
ER/PR
Negative/negative 22 (26) 1 (8)
Negative/positive 1 (1) 0
Positive/negative 12 (14) 1 (8)
Positive/positive 51 (59) 10 (83)
HER2
Negative 56 (65) 9 (75)
Positive 20 (23) 3 (25)
Missing 10 (12) 0
Triple negative
No 69 (80) 12 (100)
Yes 15 (17) 0
Unknown 2 (2) 0
Grade
1 or 2 43 (50) 4 (33)
3 43 (50) 7 (58)
Unknown 0 1 (8)
Histology
Ductal 67 (78) 12 (100)
Lobular 19 (22) 0
Inflammatory
Yes 16 (19) 1 (8)
No 70 (80) 11 (92)
Treatment characteristics, n (%)
Previous neoadjuvant chemotherapy 32 (37) 2 (17)
Radiation therapy received 64 (74) 12 (100)
Conditioning regimen
STAMP-V 52 (60) 0
ACT 19 (22) 0
Melphalan alone 3 (3) 3 (25)
Melphalan + STAMP-V 12 (14) 9 (75)
Outcomes, n (%)
RFS/PFS
At 3 years 63 (52-72) 49 (19-73)
At 5 years 53 (41-63) ———*
OS
At 3 years 82 (72-89) 73 (38-91)
At 5 years 71 (60-80) ———*
*Too few patients in stage IV had been progression-free or survived for 5
years.
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with Peripheral Stem Cell Rescuewith cycle 2, consisting of STAMP-V. Trastuzumab
was given on day 27 if the patient’s tumor was
HER2-positive. PBPCs were reinfused on day 22
(12.5% of total) and day 0 (37.5%), with administra-
tion of G-CSF, as before, starting on day 0.
Additional therapies
In patients with LABC/IBC, those with estrogen
receptor (ER)-and/or progesterone receptor (PR)-positive tumors were started on tamoxifen 20 mg
within 4-6 weeks of the day of HDCT (day 0), which
continued until recurrence or the completion of 5
years of therapy. Patients randomized to the pamidr-
onate arm received the drug at a dose of 90 mg i.v. ev-
ery 4 weeks for 24 months, with the first dose given
within 4-6 weeks of day 0. Local-regional radiation
therapy, including the primary site and supraclavicu-
lar and axillary nodal areas within 6-8 weeks of day
0 of HDCT, was recommended for all patients.
For patients receiving the tandem regimen, trastu-
zumab and antiestrogen therapy (as appropriate) were
prescribed. Patients with LABC/IBC were to undergo
local-regional radiation therapy, initiated 6-8 weeks
from cycle 2. Treatment of internal mammary nodes
was at the discretion of the treating radiation oncolo-
gist, as was the use of intensity-modulated radiation
therapy.
Patients with stage IV disease received consolida-
tive radiotherapy within 6-8 weeks of cycle 2 with stan-
dard intensity-modulated or helical tomotherapy to all
visible, responding metastatic lesions present before
HDCT. Sites demonstrating complete response were
not treated. All visible sites received 180-220 cGy/
day, to a total dose of 4000-5000 cGy.Statistical Considerations
Survival outcomes included RFS/PFS and OS, cal-
culated from time of initial PBPC rescue. For RFS/
PFS, the events included death or disease recurrence
(disease progression for patients with stage IV disease),
whichever came first. Data for patients who did not ex-
perience disease recurrence or progression and were
still alive were censored at the date of last follow-up.
For OS, data for patients who were still alive were cen-
sored at the date of last follow-up. The log-rank test
was used in univariate survival analyses to test the asso-
ciations between survival outcomes and various clinical
variables. Survival rates were estimated using the
Kaplan-Meier method. Cox regression analysis was
used to calculate hazard ratios (HRs) and their 95%
confidence intervals (CIs) in univariate and multivari-
ate analyses.RESULTS
Patient Characteristics
A total of 98 patients (71 on the single trial and 27
on the tandem trial) were evaluable for toxicity and
outcome. Follow-up data were collected up to the
end of 2010. Patient characteristics are presented in
Table 1.
On the single regimen, 19 patients received ACT
before this arm was closed because of toxicities, and
52 patients received HDCT with STAMP-V. On the
Figure 1. RFS and OS for patients with stage III disease.
Table 2. Outcome by Univariate Analysis in Patients with
Stage III Disease
RFS 5-Year DFS (95% CI) HR (95% CI) P value
Stage
IIIA 84% (49%-96%) 1 .048*
IIIB 63% (24%-87%) 2.87 (0.48-17.18)
IIIC 45% (32%-57%) 4.76 (1.14-19.81)
ER/PR
Negative 30% (12%-50%) 1 .004*
Positive 60% (47%-72%) 0.4 (0.21-0.76)
HER2
Negative 54% (39%-66%) 1 .87
Positive 51% (26%-71%) 1.20 (0.58-2.50)
Missing 0.97 (0.37-2.53)
Grade
1 or 2 53% (37%-67%) 1 .97
3 52% (36%-66%) 1.01 (0.54-1.88)
HDCT
ACT 47% (24%-67%) 1 .55
STAMP-V 55% (41%-68%) 0.71 (0.34-1.47)
Melphalan/STAMP-V† 53% (23%-77%) 1.03 (0.38-2.81)
OS 5-Year OS (95% CI) HR (95% CI) P value
Stage
IIIA 92% (54%-99%) 1 .11
IIIB 89% (43%-98%) 1.09 (0.1-12.08)
1276 Biol Blood Marrow Transplant 18:1273-1280, 2012A. VanderWalde et al.tandem regimen, 27 patients received melphalan, but
6 of these patients (22%) were unable to receive the
second cycle with STAMP-V because of either death
(1 patient, due to sepsis) or disease progression
(5 patients). On the tandem regimen, patients with
HER2-positive breast cancer were also treated with
trastuzumab. All patients received some form of radia-
tion to affected areas as part of treatment.IIIC 65% (52%-76%) 3.42 (0.81-14.39)
ER/PR
Negative 38% (18%-58%) 1 <.001*
Positive 83% (70%-90%) 0.26 (0.13-0.54)
HER2
Negative 73% (59%-83%) 1 .61
Positive 67% (41%-84%) 1.49 (0.66-3.34)
Missing 70% (33%-89%) 1.03 (0.34-3.09)
Grade
1 or 2 77% (60%-87%) 1 .18
3 66% (49%-78%) 1.65 (0.79-3.43)
HDCT
ACT 63% (38%-80%) 1 .61
STAMP-V 75% (60%-84%) 0.67 (0.31-1.48)
Melphalan/STAMP-V† 75% (41%-92%) 0.86 (0.23-3.24)
*Difference attained statistical significance.
†Patients intended to be treated with melphalan + STAMP-V.Efficacy
The median follow-up time was 84 months (range,
6-136 months) for living patients with LABC/IBC and
40 months (range, 24-62 months) for those withMBC.
In patients with LABC, 5-year RFS and OS were 53%
(95%CI 41%-63%) and 71% (95%CI 60%-80%), re-
spectively. Separating out patients by LABC stage us-
ing American Joint Committee on Cancer version 7
criteria, the 5-year RFS was 84% for stage IIIA, 63%
for stage IIIB, and 45% for stage IIIC, and corre-
sponding 5-year OS was 92%, 89%, and 65%
(Figure 1). In patients with stage IV oligometastatic
disease, 3-year PFS and OS were 49% (95% CI,
19%-73%) and 73% (95% CI, 38%-91%), respec-
tively (Figure 2).
Disease and treatment characteristics were exam-
ined for association with RFS and OS in patients
with stage III cancer (Table 2). Those with stage
IIIC disease had a significantly worse RFS (HR,Figure 2. PFS and OS for patients with oligometastatic (stage IV)
disease.4.76; P 5 .017) and marginally significantly worse
OS (HR, 3.42; P5 .073) than those with stage IIIA dis-
ease. ER/PR-positive disease was significantly associ-
ated with better 5-year RFS (60% versus 30%; P\
.01) and OS (83% versus 38%; P\ .001) than ER/
PR-negative disease. No other factor, including
HER2 status, tumor grade, histopathology, neoadju-
vant chemotherapy, and type of HDCT, demonstrated
statistically significant differences in either RFS or OS.
In multivariate Cox regression models, disease stage
(IIIC versus IIIA/B) and ER/PR status continued to
be significantly associated with RFS and OS (Table 3).Toxicity
Table 4 shows a breakdown of grade $3 toxicities
possibly related to treatment, stratified by HDCT
regimen. There were no unexpected hematologic
toxicities or primary or secondary graft failures, and
none of the patients developed myelodysplasia or sec-
ondary hematologic malignancies.
Table 3. Multivariate Cox Regression Models for Patients
with Locally Advanced Disease
Outcome Variable HR (95% CI) P value
RFS Stage (IIIC versus IIIA/B) 3.04 (1.19-7.78) .020
ER/PR (+ versus 2) 0.38 (0.20-0.73) .004
OS Stage (IIIC versus IIIA/B) 3.30 (1.00-10.9) .05
ER/PR (+ versus 2) 0.26 (0.13-0.54) <.001
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grade $3 cytopenia, as would be expected in am
HDCT-treated patient population. Similarly, high
rates of electrolyte abnormalities (84% for ACT,
50% for STAMP-V, and 44% for melphalan 1
STAMP-V) and febrile neutropenia (84%, 48%, and
52%, respectively) were noted. ACT was additionally
associated with severe mucositis (84%) and esophagitis
(79%). STAMP-V was better tolerated overall, with
the most common other grade$3 toxicities, including
nausea/vomiting (21%) and infection (16%). Specifi-
cally, in the group receiving melphalan 1 STAMP-V,
common high-grade toxicities included anorexia/
weight loss (41%), nausea/vomiting (37%), mucositis
(33%), infection/sepsis (30%), and diarrhea (19%).









Altered mental status 3 (16)† 1 (2) 0 (0)
Anorexia/weight loss 6 (32) 11 (21) 11 (41)
Diarrhea 0 (0) 0 (0) 5 (19)
Dyspnea (shortness of breath) 0 (0) 2 (4) 0 (0)
Edema/weight gain 0 (0) 2 (4) 0 (0)
Electrolyte abnormalities 16 (84) 26 (50) 12 (44)
Esophagitis 15 (79) 2 (4) 1 (4)
Fatigue (asthenia, lethargy, malaise) 1 (5) 7 (13) 10 (37)
Febrile neutropenia 16 (84) 25 (48) 14 (52)
Hemorrhage 5 (26) 7 (13) 2 (7)
Hypertension 2 (11) 2 (4) 0 (0)
Hypotension 0 (0) 3 (6) 1 (4)
Hypoxia 1 (5) 4 (8) 1 (4)
Infection/sepsis 3 (16) 10 (19) 8 (30)‡
Liver dysfunction/failure 2 (11) 0 (0) 1 (4)
Mucositis 16 (84) 3 (6) 9 (33)
Myalgia 1 (5) 2 (4) 3 (11)
Nausea/vomiting 4 (21) 13 (25) 10 (37)
Neuropathy 2 (11) 0 (0) 0 (0)
Pain, other 1 (5) 4 (8) 4 (15)
Pain, bone/joint 2 (11) 0 (0) 3 (11)
Rash 0 (0) 2 (4) 0 (0)
Renal failure 0 (0) 0 (0) 1 (4)




0 (0) 2 (4) 0 (0)
*Patients treated with melphalan alone were combined with those
treated with melphalan + STAMP-V.
†Due to narcotic use for treatment of mucositis.
‡One patient in the tandem group died of transplantation-related sepsis.
§One patient in the tandem group developed a secondary papillary
thyroid carcinoma after HDCT.on the tandem protocol, and 1 patient developed papil-
lary thyroid carcinoma after tandem HDCT.DISCUSSION
We have reported the outcomes and toxicities of
HDCT regimens followed by stem cell rescue that
were conducted under 2 sequentially developed proto-
cols in patients with high-risk breast cancer (treated
with ACT versus STAMP-V HDCT on the first trial
and melphalan 1 STAMP-V on the second trial) and
who had oligometastatic disease (treated with melpha-
lan 1 STAMP-V tandem regimens). Our data com-
pare favorably with data in historical controls using
standard-dose chemotherapy for the treatment of
high-risk cancer. Our median follow-up time is longer
than that in most previous large randomized trials of
HDCT in high-risk populations. According to data
from the National Cancer Data Base for patients diag-
nosed in 2001-2002, the 5-year OS rate for patients
with stage IIIC breast cancer from time of diagnosis
is only 49% [4]. This contrasts with our cohort, which
displayed a 5-year survival rate of 65% in such cancers.
This confirms our previous observations [12], and the
results are encouraging given the high rate of IBC seen
in our cohort (17 IBC/86 LABC), given that most
other previous HDCT trials excluded patients with
IBC. The favorable safety data with our approach
clearly contributed to the overall positive outcome, al-
though we must be cautious when interpreting data
generated from a single institutional, nonrandomized,
retrospective dataset. The relative safety of our ap-
proach similarly contributed to our 3-year OS rate of
73% with tandem HDCT in patients with oligometa-
static disease, which compares favorably with the
30.1% 3-year survival rate seen in all patients with
stage IV breast cancer in the general population
[4,18,20]. We found no differences in outcome based
on disease site (visceral versus nonvisceral), possibly
due to the limited number of cases in our series. The
relatively small number of selected metastatic breast
cancer patients in our series, as well as the lack of
matched controls, does not allow for generalized
conclusions. Also possibly due to our small sample
size, we found no statistically significant benefits of
the use of adjuvant bisphosphonates, or for the use of
tandem versus single regimens (data not shown).
Further testing of both concepts remains worthwhile.
Given the time frame of the accrual of most of our
patients with LABC/IBC on the first trial,
trastuzumab was prescribed to only 5 of the 20
HER2-positive patients (data not shown); thus, we
can postulate that PFS and OS might have been im-
proved with greater use of trastuzumab.
Previous studies of HDCT have been plagued by
concerns of selection bias and a lack of RCTs. How-
ever, in the past decade, long-term follow-up data
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and metastatic disease [21]. In high-risk primary dis-
ease, 15 trials involving HDCT have been reported
[22-36]. The study finding the greatest benefit from
HDCT was the West German Study Group (WSG)
AM-01 Study [27]. Of 403 patients with at least 9 pos-
itive nodes, 201 received tandem cycles of high-dose
epirubicin-cyclophosphamide-thiotepa with PBPC
rescue after each cycle, and 202 received conventional
treatment with epirubicin-cyclophophamide and
CMF. After a median follow-up of 48.6 months,
4-year EFS was 60% in the high-dose group and
44% in the conventional group (P \ .001). Alone
among randomized trials of HDCT, the WSG AM-
01 Study also found a statistically significant OS ad-
vantage (4-year OS, 75% versus 70%; P 5 .02) [27].
RFS/EFS benefits have been reported in 2 other
HDCT trials, 1 by Rodenhuis et al. [29] using cyclo-
phosphamide, thiotepa, and carboplatin, and the other
by Roche et al. [36] using cyclophosphamide, mitoxan-
trone, and melphalan. Neither trial demonstrated an
OS benefit after a median follow-up of 7 years and
2.75 years, respectively (although the Dutch trial
reported an OS advantage for the subset of triple-
negative patients [29]). These trials had differing
inclusion criteria, with 1 trial requiring 4 or more pos-
itive nodes, and the other requiring more than 7 posi-
tive nodes. Whereas additional RTCs have shown
trends in favor of HDCT [22,31,33,34] compared
with conventional-dose chemotherapy in mature
follow-up, other trials reported less-favorable results
[6,23-26,30-32,35].
A Cochrane Reviews meta-analysis of 5111 pa-
tients in 13 RCTs performed in 2006 found that a sig-
nificant EFS benefit was seen in favor of the HDCT
arms at various follow-up points, though without OS
differences. However, treatment-related mortality
was higher in the HDCT arms than in the conven-
tional dosing arms (2.5% versus 0.1%) [37]. Amore re-
cent meta-analysis of 15 trials by Berry et al. [38]
included data on a total of 6210 patients. An absolute
EFS benefit of 13% was seen in favor of HDCT
(HR, 0.87; P 5 .001) after a median follow-up of 6
years, with a nonsignificant trend toward anOS benefit
(HR, 0.94; P 5 .13). Because of the heterogeneity of
dose-intensity regimens used in these trials, the au-
thors also measured outcome using summation dose-
intensity methodology. After adjusting for covariates,
higher dose intensity was associated with decreased
rate of recurrence (HR, 0.85 per 1 unit increase; P\
.001), as well as with a nonsignificantly increased OS
(HR, 0.91; P 5 .033).
Various investigators also have performed sub-
group analyses to determine whether any factors might
lead to higher efficacy of HDCT in high-risk disease.
Gluz et al. [39], in a retrospective analysis of the
WSG AM-01 Study, found that the benefits ofHDCT appeared most pronounced in patients with
a basal-like phenotype (ER/PR-negative, HER2-
negative, and basal cytokeratin-positive) and in those
with grade 3 tumors. Others have speculated that pa-
tients with triple-negative disease are the most likely
to receive a benefit from HDCT [40]. Although the
patients in our cohort with ER/PR-positive tumors
did significantly better than those with ER/PR-
negative tumors, some of the relatively long DFS
seen in the former group is likely due to the fact that
patients with ER/PR-positive cancer tend to do better
overall than patients with triple-negative disease. Pa-
tients with lower-stage (IIIA and B) disease (driven pri-
marily by the number of lymph nodes, except in IBC)
did demonstrate better RFS/OS. Interestingly, pa-
tients with high-grade tumors did not do worse than
those with lower-grade tumors in this study. This
might have been due to small sample size, or perhaps
high-grade disease was more responsive to HDCT.
Berry et al. [38] did not find any subset of patients
who clearly benefited more than others from
HDCT, although molecular markers were largely
unexamined in that study.
In metastatic breast cancer, in addition to selective
phase II trials [18], a number of RCTs also have been
performed in the last decade [41-47]. Generally, these
studies found improved PFS/EFS in favor of HDCT,
with a median additional EFS of 1-8 months. In
addition, 1 of these trials demonstrated an OS
benefit of .2 years (median OS for HDCT versus
standard, 44 months versus 19 months; P 5 .02) [43],
although the other RCTs failed to show an OS benefit.
A Cochrane Database meta-analysis performed in
2004 including 6 trials and 850 patients found a signif-
icant EFS benefit at both 1 and 5 years, with a trend to-
ward an OS benefit starting at 5 years (P 5 .08).
However, treatment-related mortality was higher in
the HDCT arm than in the conventional treatment
arm (3.5% versus 0.4%) [14]. Treatment-related mor-
tality was zero in the small subset of patients withMBC
in our cohort. In a recent meta-analysis of 6 RCTs for
MBC, Berry et al. [48] reported on the outcome of 866
patients. As in high-risk disease, the authors found
a statistically significant improvement in PFS (0.91
year versus 0.69 year; P\ .001), but not in OS (2.16
years versus 2.02 years; P5 .08). The authors were un-
able to identify any subgroup of patients that showed
a clear benefit fromHDCT. Again, molecular markers
were largely unexamined in that study.CONCLUSION
HDCT combined with PBPC rescue was safe in
our long-term experience and generally effective in de-
creasing the risk of disease recurrence or disease pro-
gression in patients with high-risk or oligometastatic
Biol Blood Marrow Transplant 18:1273-1280, 2012 1279Long-Term Survival after High-Dose Chemotherapy
with Peripheral Stem Cell Rescuebreast cancer. Not all HDCT regimens are created
equal, however; the ACT regimen was poorly tolerated
and holds little promise in future HDCT trials. The
favorable long-term PFS/RFS and OS in our highly
selected patient population warrant further assess-
ment. Validation should be pursued in well-defined
subgroups of patients, both molecularly defined and
biologically selected. The former might include, for
example, those with triple-negative phenotype and/or
basal/claudin-low genotype, whereas the latter might
include premenopausal patients, patients with inflam-
matory breast cancer, those with residual disease after
neoadjuvant chemotherapy, and those with responding
oligometastatic nonvisceral metastatic disease. These
approaches will be best tested in prospective, random-
ized, multi-institutional trials.ACKNOWLEDGMENTS
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